1	Quetiapine dose optimisation during gestation: a pharmacokinetic modelling study
2	
3	
4	Raj K. S. Badhan <sup>1</sup> Hannah Macfarlane <sup>1</sup>
5	
6 7	<sup>1</sup> Medicines Optimisation Research Group, Aston Pharmacy School, Aston University, Birmingham, B4 7ET, United Kingdom.
8	
9	
10	Correspondence:
11 12 13 14 15 16 17 18 19 20 21	Dr Raj Badhan Aston Pharmacy School Life and Health Sciences Aston University Birmingham B4 7ET UK Telephone: +44 121 204 3288 E-mail: <u>r.k.s.badhan@aston.ac.uk</u>

### 23 ABSTRACT

Objectives: The second generation antipsychotic quetiapine has been demonstrated to undergo gestation related changes in pharmacokinetics. This study applied pharmacokinetic modelling principles to investigate the mechanism of these changes and to propose new dosing strategies to counteract these changes

Methods: A pharmacokinetic modelling approach was implemented using virtual population
groups. Changes in quetiapine trough plasma concentration during gestation were quantified
across all trimesters and dose adjustment strategies were applied to counteract these changes
by targeting a therapeutic range of 50-500 ng/mL throughout gestation

Findings: The application of the model during gestation predicted a decrease in trough concentration. A maximum decrease of 58 % was predicted during trimester 2, and being associated with a statistically significant decrease in oral clearance at gestation week 25, 204  $L/h \pm 100.8$  L/h compared to non-pregnant subjects, 121.9 L/h  $\pm$  51.8 L/h. A dosing optimisation strategy identified that dose increases to 500-700 mg twice daily would result in 32-55 % of subjects possessing trough concentration in excess of 50 ng/mL.

Conclusions: Quetiapine doses in pregnancy should be increased to 500-700 mg twice daily to
 counteract a concomitant increase in metabolic clearance, increase in volume of distribution
 and decrease in plasma protein binding.

## 42 **KEYWORDS**

43 Quetiapine; pregnancy; pharmacokinetics; PBPK; dose optimisation.

### 44 **1. INTRODUCTION**

Quetiapine is a second generation antipsychotic that was first approved by the US Food and
Drug Administration (FDA) in 1997 for the management of schizophrenia in both adults and
adolescents in addition to a range of other psychiatric disorders [1, 2].

48 Several reports have highlighted that quetiapine is the most commonly prescribed atypical 49 antipsychotic in women of childbearing age [3-5]. A key advantage of quetiapine over other 50 atypical antipsychotics is that it is unlikely to be associated with extrapyramidal symptoms and

51 is prolactin (PRL)-sparing but is associated with weight gain [6].

52 However, the use of pharmacological interventions for psychiatric disorders during pregnancy

is particularly challenging, given the need to balance stabilisation of maternal mental state with
the potential teratogenic effects of the prescribed drug. Often, this results in the cessation of

treatment during the gestational period, particularly in trimester 1 [7].

In the wider context of pregnancy, approximately 15 % of women have some form of 56 psychiatric illness with up to 13 % of women taking prescribed psychotropic pharmacological 57 interventions [8, 9]. Clinicians are likely to be faced with the possibility of treatment (or not) 58 within the perinatal setting. However, clinical studies have demonstrated that pregnancy should 59 60 be considered as a 'high-risk' period for relapse in the context of a discontinuation of any maintenance treatment options [10-14]. This is particularly important given that recent reports 61 62 in the UK have suggested that 1 in 25 women (aged 20-35 years) who die by suicide, do so during the perinatal periods (conception-pregnancy and post-natal) [15]. And further, that poor 63 mental health during gestation is highly correlated with poor mental health postnatally [14]. 64

Mounting evidence supports the notion that cessation of therapy during pregnancy may be 65 detrimental to the mother for some antipsychotics, a choice which requires consideration of the 66 67 risks and benefits of pharmacological interventions during gestation [7, 16, 17]. Although the risks of antipsychotic use during pregnancy may be outweighed by the clinical benefits, 68 gestation brings about significant changes in the physiology of the mother which can have 69 drastic changes on the pharmacokinetics of drugs administered during pregnancy. Quetiapine 70 is primarily metabolised by the phase-1 Cytochrome P450 enzyme CYP 3A4 [18], and 71 gestation can result in a significant increase in the expression of CYP3A4 [19-21] by between 72 25-40 % [22], which would enhance quetiapine metabolic clearance and hence results in a net 73 reduction in quetiapine plasma concentrations. An obvious change occurs in body composition 74 with a 40-50 % increase in plasma volume [23, 24] throughout gestation along with a 75

concomitant increase in body fat, approximately 4 kg, resulting in alterations of the volume of

distribution of hydrophilic and lipophilic drugs during gestation which would generally reduce

78 plasma drug concentration In addition, decreases in the plasma-proteins albumin and alpha-1-

acidic glycoprotein will in turn increase the free drug fraction and directly influence the volume

80 of distribution [25-27].

81 In a recent retrospective study, the plasma levels of a range of antipsychotics were analysed

82 during gestation and it was identified that significant decreases in serum levels were evident,

particularly for quetiapine, which decreased by up to 70 % in trimester 3 [28].

84 At present, there are no well-controlled or reliable studies of quetiapine use during pregnancy, 85 and because of this reason the FDA have classified quetiapine as a category C drug, suggesting it should be used during pregnancy only if the benefits to the mother outweigh any risks to the 86 87 patient. However, the US Office of Paediatric Therapeutics conducted a review of 220 adverse reports associated with quetiapine, which were submitted to the FDA adverse event reporting 88 systems and identified that there doesn't seem to be a risk of congenital anomalies but 89 acknowledge the limited nature of the data reported [29]. Further, the clinical toxicology 90 database TOXBASE® (https://www.toxbase.org) from the National Poisons Information 91 Service Unit [30], has provided guidance for the use of quetiapine during gestation and does 92 not advocate its cessation necessarily, rather places emphasis on the consideration of the risk 93 of relapse on cessation compared to the benefits to the mother and child during gestation. 94

We have, for the first time, applied the principles of mechanistic pharmacokinetic modelling and virtual clinical trials to better elucidate the causative effects of this decrease in plasma quetiapine levels during gestation, to provide a clinically relevant dosing adjustment strategy that could be implemented to maintain plasma quetiapine levels during gestation.

99 The objectives of this study were to: (i) develop a robust and validated pharmacokinetic model 100 for quetiapine; (ii) identify a suitable therapeutic window for quetiapine and (iii) explore the 101 impact of gestation on quetiapine plasma levels and address any alterations with clinically 102 appropriate dose adjustments.

### 104 2. METHODS

Simulations were performed using the virtual clinical trial simulator Simcyp (Simcyp® Ltd, a 105 Certara company, Sheffield, UK, Version 16). The 'Healthy Volunteer' population group was 106 used for 'non-pregnant' females and the 'Pregnancy' population group utilised for all 107 'pregnancy' studies. The latter population group included necessary gestational dependant 108 changes in physiology, such as blood volume and organ/tissue perfusion and enzyme/protein 109 expression, which are thought to play a role in altering the pharmacokinetics of drugs [31-34]. 110 A 4-stage modelling approach was implemented. A previously validated model of quetiapine 111 [35] was utilised with adaptations through the inclusion of CYP3A5 metabolic clearance 112 113 pathway [36, 37].

- 114

### 115 2.1 Step 1: Validation of quetiapine

In order to implement a pregnancy model within Simcyp the previously validated quetiapine 116 117 model [35] required modification as the model primarily implemented a minimal-PBPK model, which does not allow consideration of a distinct foetal/placental tissue compartment and 118 physiological alterations in other maternal tissues during gestation. For simulations in pregnant 119 subjects, a full-PBPK distribution model was required and therefore tissue-partition coefficient 120 (Kp) estimates were calculated using the Rogers and Rowland approach [38, 39]. These were 121 then parameter estimated (using a Weighted Least Square (WLS) method and the Nelder-Mead 122 minimisation approach) through the optimisation of a tissue partition coefficient scalar, Kp<sub>scalar</sub>, 123 using a total of 3 single dose studies and 1 multi-dose study: (i) 12 men (24-42 years old) dosed 124 a single oral dose of 25 mg [40]; (ii) 15 men and 3 women (29-63 years old) dosed at 25 mg 125 twice daily on day 1, 50 mg twice daily on day 2, 100 mg twice daily on day 3, 200 mg twice 126 daily on day 4 and 300 mg twice daily on day 5 until day 10 [40]; (iii) 10 men (35-55 years 127 old) dosed at 25 mg three times daily (TID) (6 am, 2 pm and 10 pm) on day 1 and dose escalated 128 to 50 mg TID on day 2, 75 mg TID on day 3, 100 mg TID on day 4 and by 50 mg increments 129 daily until 250 mg TID on days 7 and 8 [41]; (iv) 11 men and 2 women (19-58 years) dosed at 130 25 mg twice daily (BD) on day 1 and dose escalated to 50 mg BD on day 2, 75 mg BD on day 131 3, 100 mg BD on day 4 and by 50 mg increments daily until 300 mg BD on 8 until day 21 [42]. 132 133

Model simulations were run to match the reported age range and patient number reported by 134 each study. However, in the absence of this information, a default trial size of 100 subjects 135 (10x10 design) aged 20-40 years old was used. 136

137	Quetiapine model parameters can be found in Supplementary Materials: Section 1.
-----	---

138

139

### 140 2.2 Step 2: Validation of CYP3A5 metabolic clearance modification

141 To further validate the appropriateness of modifications made to the CYP3A5 intrinsic clearance [37], three retrospective clinical drug-drug interactions studies were used to further 142 validate the model and consisted of: (i) ketoconazole dosed alone for days 1 to 3 and in 143 144 conjunction with quetiapine on day 4 [40]; (ii) quetiapine dose escalated to 300 mg twice daily by day 5 and maintained for 34 days. Thereafter carbamazepine initiated with a 200-mg dose 145 146 on the evening of day 9, followed by 200 mg twice daily on days 10-12, and increased to 200 mg three times daily from days 13-33 with a final dose on the morning of day 34 [40] and (iii) 147 quetiapine dose escalated from 25 to 250 mg three times daily by day 10 and maintained until 148 day 23 with phenytoin administered at 100 mg three times daily on days 13-33 in conjunction 149 with quetiapine [41]. 150

151 Where possible, trial design and sampling duration was replicated from the original studies.

152

153 2.3 Step 3: Validation during gestation

# A recent report by Westin *et al* [28] retrospectively collated serum level of antipsychotics before, during and after pregnancy. Data for quetiapine consisted of 66 measurements during pregnancy, 11 during the first 12 weeks following pregnancy and 144 at baseline, from 33 women. Subjects were stabilised on 400 mg/daily. This data was extracted, pooled and utilised as 'observed' data for validation purposes.

In simulating quetiapine pharmacokinetics during gestation, a 38-week trial design was
utilised, with simulations conducted using a 10x10 trial design with dosing adjusted on a daily
basis by 50 mg/day to 200 mg twice daily for all subjects.

For all dosing approaches in pregnancy, unless otherwise stated, the pre-dose (trough) plasma concentration was ascertained 10 hours following each dose. For assessment of plasma concentration, all concentrations were dose adjusted to the defined daily dose (DDD), whereby the simulated plasma concentration was divided by the daily dose and subsequently multiplied by the DDD (the average maintenance dose per day for its main indication in adults)[43].

For comparison, the trial design was also replicated for Healthy Volunteer population of non-pregnant females dosed under the same dosing strategy.

169 2.4 Step 4: Dose adjustment during gestation

170 Limited data currently exists purporting to show a relationship between plasma quetiapine levels and clinical responses and these have recently been summarised in a review by Mauri et 171 172 al (2018) [44]. Further, a suggested therapeutic window of between 100-500 ng/mL has been proposed by the Arbeitsgemeinschaft für Neuropsychopharmakologie und 173 174 Pharmakopsychiatrie (AGNP) [45] and this was adopted as the potential therapeutic window. However, the region of 50-100 ng/mL was also considered as a 'borderline' range, given that 175 176 doses in the range of 150-800 mg daily can yield mean trough concentrations in the range of 27-387 ng/mL [46-50]. Although the FDA advocated maximum recommended dose is 800 mg 177 178 daily [51], a number of studies have assessed the safety of higher doses in non-pregnant subjects to a maximum of 1400 mg daily [52-54] with no significant safety concerns. 179

In a recent case report the need for dose adjustment to be made during pregnancy for women 180 with bipolar disorder was highlighted [55], with dose escalation by up to an additional 350 181 mg/daily in some cases to maintain symptom control during gestation. Further, previous 182 reports of foetal exposure of quetiapine have occurred at dose ranges of 300-600 mg/day during 183 gestation with no harmful effects on the new-born [56-59]. Interestingly a dose of 1200 mg/day 184 was also used at mid-pregnancy (21 weeks gestation) as identified in a case report by Cabuk 185 [60], which resulted in a normal birth. Although mainly case reports, these serve as useful 186 187 guidance for potential dose escalation strategies required.

188

In order to assess the requirement for dose optimisation, simulations were conducted with 100 subjects (10x10 design) aged 20-30 years. Simulations were commenced on day 1 of gestation and terminated on day 1 of week 39. Dose escalation studies included 'baseline' simulations of 200 mg twice daily and subsequently by 50 mg increments every 3 days to a maximum of 700 mg twice daily. Data was sampled on the final 24 hour period of every 5<sup>th</sup> week up to and including week 38.

### 195 2.5 Predictive Performance

For all simulations in steps 1-3, a prediction of a pharmacokinetic metric to within two-fold
(0.5-2.0 fold) of published clinical data was generally accepted as part of the 'optimal'
predictive performance [61-63].

### 199 2.7 Visual Predictive Checks

Model predictions in step 1-3 were compared to clinical studies using a visual predictive checking (VPC) strategy [64]. In this approach, the predicted mean/median and 5<sup>th</sup> and 95<sup>th</sup> percentiles of the concentration–time profiles (generated from Simcyp®) were compared against the observed data for any validation data sets. The prediction was assumed to be valid when the predicted data points overlapped with the observed data sets.

### 205 2.8 Data and statistical analysis

All observed data obtained from clinical studies were extracted using WebPlotDigitizer v.3.10 (<u>http://arohatgi.info/WebPlotDigitizer/</u>). Statistical analysis was conducted using a nonparametric Kruskal-Wallis with a Dunn's multiple comparison post-hoc test. Statistical significance was confirmed where a P < 0.05 was computed.

210

### **3. RESULTS**

### 212 **3.1** Step 1: Validation of quetiapine

A previously published quetiapine model was adapted with the incorporation of a full-PBPK 213 model in order to predict tissue partition coefficient and enable a full mechanistic model to be 214 215 utilised, in addition to the incorporation of a CYP3A5 metabolic pathway. The adapted file was validated against a range of published clinical studies using the Simcyp Healthy Volunteer 216 population group (See section 2.1). For all single and multi-dose studies (Supplementary 217 Materials: Section 2 Figure S1) along with drug-drug interactions simulations (Supplementary 218 Materials: Section 2 Figure S2), the simulated plasma concentration-time profiles were 219 successfully predicted to within the observed range for each study and model-predicted  $t_{max}$ , 220 C<sub>max</sub>, and AUC were predicted to within 2-fold of the reported parameters for each study, 221 confirming successful validation (Table 1). 222

223

When compared to non-pregnant females (baseline), the median steady-state trough plasma concentrations of quetiapine decrease during gestation (Figure 1) with a statistically significant difference between baseline and the mid-point of trimesters 1-3 (final day of weeks 6, 20 and 32 respectively) (P < 0.001, Dunn's post-hoc comparison) (Table 2). During gestation the predicted median plasma concentration decreased by between 52-58 %.

The reduced plasma concentration during gestation was associated with a concomitant increase 229 in oral clearance (CL/F) which was significantly different from baseline from gestational week 230 10 onwards (P < 0.05, Dunn's post-hoc comparison) and reached a maximum at GW 25, 204 231  $L/h \pm 100.8 L/h$  compared to baseline, 121.9  $L/h \pm 51.8 L/h$  (Figure 2A). Further, changes in 232 volume of distribution are significant from week 25 onwards, rising from a baseline of 329.2 233  $L \pm 71$  L to 368.4 L  $\pm 71.3$  L at GW 38 (Figure 2B). A statistically significant increase in 234 unbound fraction was also noted from GW 10 onwards and with fu<sub>plasma</sub> being 21-26 % greater 235 from weeks 30 onwards ( $fu_{plasma} = 0.0218-0.0225$ ) (Figure 2C). 236

- Understanding the importance of maternal physiological changes during gestation on 237 quetiapine pharmacokinetics is clearly multifaceted. Therefore we conducted a sensitivity 238 analysis using a non-pregnant and pregnant (GW: 10, 20 and 30) female population group 239 240 where we directly examined the impact of variation in the CYP 3A4 hepatic abundance (137 pmol/mg protein to 180 pmol/mg protein, representing a 30 % increase from baseline levels) 241 242 and Kp scalar (1 to 3, representing a Vss range of 3.8 L/kg to 11 L/kg; implemented using Simcyp estimated Kp's) (Figure 3). When considering non-pregnant subjects, the trough serum 243 concentrations are largely sensitive to changes in both Vss (Kp scalar) and CYP 3A4 244 abundance, although the former has a greater influence. Conceptually, an increase in Vss 245 would result in a net reduction in peak  $(C_{max})$  plasma concentrations with a concomitant shift 246 in the distribution and elimination phases of the drug. However, this shift in the latter phases 247 of the plasma concentration-time profile would result in a net increase in the trough plasma 248 concentration ( $C_{min}$ ) (Figure 3A). At a fixed hepatic abundance, for example the default hepatic 249 abundance in healthy (non-pregnant) subjects of 137 pmol/mg protein, any increase in Kp 250 scalar (and hence increased in Vss) would increase the C<sub>min</sub> (Figure 3B). However, during 251 gestation the increase in CYP 3A4 hepatic abundance would negate the impact of an increase 252 in Vss on the  $C_{min}$ , and result in a net reduction in trough plasma concentration (Figure 3). 253
- 254
- 255 **3.4** Step 4: Dose adjustment during gestation

In order to address the reduced plasma concentration during gestation, a dose escalation strategy was explored, whereby doses were increased by 50 mg increments every 3 days to a maximum of 500 mg twice daily, from a baseline dose of 200 mg twice daily.

As expected, the dose increase during gestation resulted in an increase in median plasma concentration (Figure 4). A dose increase of 300 mg (i.e. 500 mg twice daily) was required to yield > 70 % of subjects with a trough plasma concentration in excess of 50 ng/mL throughout
gestation (Table 3). However, a dose increase of 500 mg (i.e. 700 mg twice daily) was required
to ensure >60 % of subjects possessed a trough plasma concentration in excess of 100 ng/mL
throughout gestation (Table 3).

- 265
- 266

### 267 4. **DISCUSSION**

The decision to use any pharmacological intervention during pregnancy is challenging for the mother in addition to the prescriber and requires clear knowledge of potential harmful effects on the developing foetus and risks such as the development of gestational diabetes. However, the choice to continue treatment or not, can be overshadowed by the clinical need for therapy during gestation, and the potential consequences of withdrawing treatment [13, 14].

Gestation brings about clear physiological changes which are known to alter the pharmacokinetic profile of drugs. However, the consequences of such changes are often difficult to ascertain clinically in a controlled trial for obvious ethical reasons. However, in an attempt to assess the potential impact of pregnancy on antipsychotic therapy, the use of robust mechanistic pharmacokinetic models allows for a prospective assessment of the potential impact and changes in plasma concentrations.

A recent report by Westin *et al* [28] examined the plasma concentrations of antipsychotics during gestation from retrospective analysis of therapeutic drug monitoring (TDM) clinical data from Norway. They identified that quetiapine and apriprazole exhibited a significant decrease in plasma concentrations during gestation, by between 50-80 % by trimester 3. Further decrease were noted for perphenazine and haloperidol, but this was limited by the number of TDM measurements available. Nevertheless, the potential for gestation-related decrease in antipsychotic plasma concentrations was noted.

286

Given the lack of more detailed clinical studies examining these phenomena, this study applied the principle of pharmacokinetic modelling to prospectively assess the use of quetiapine in pregnancy population groups and attempted to relate changes in plasma concentrations during gestation to a potential therapeutic window region. The Simcyp Pregnancy PBPK model has been utilised by our group [65] and others [32, 33] for prediction of the impact of changes in 292 plasma concentrations associated with gestation, however this is the first time it has been293 utilised in the context of quetiapine.

The model developed incorporated adaptations to two existing quetiapine PBPK models [35, 37] and was validated against single and multiple dose studies (Supplementary Materials: Section 2 Figure S2). The resulting predictions were within 2-fold of those reported along with appropriate VPC confirming population level variability in plasma concentrations were appropriately predicted in relation to the clinically reports variability. Further, the inclusion of the revisions to the CYP 3A5 component [37] were able to recapitulate the impact of appropriate DDIs on plasma concentrations (Supplementary Materials: Section 2 Figure S3).

301 To our knowledge, Westin et al [28] is the only publication (to date) containing quetiapine plasma concentrations throughout gestation and this was used as the basis for validating the 302 303 quetiapine pregnancy PBPK model. Simulations were run for the entire gestation period (38 weeks) with sampling of the first day on each week for every 5 weeks reported (Figure 1). For 304 non-pregnant subjects (baseline), model predicted plasma concentrations ( $54.59 \text{ ng/mL} \pm 26.98$ 305 ng/mL) were within 2-fold of those reported by Westin et al [28] (75.6 ng/mL) (Table 2), whilst 306 also spanning across a similar range. Westin et al [28] reported a 22 %, 57 % and 76 % decrease 307 in mean plasma concentration at for trimesters 1, 2 and 3 respectively. Using the PBPK model 308 we demonstrated a similar decrease of 52-58 % across gestation, although the predicted 309 decrease for trimester 1 was greater than that reported [28]. Nonetheless, the trend throughout 310 gestation for a decrease in plasma concentration was similar, and represents an important 311 phenomenon, which is likely to result in sub-therapeutic plasma concentrations if we assume a 312 lower limit of the therapeutic window to be 100 ng/mL. 313

In order to identify the cause of this change in plasma concentrations during gestation, we first examined the impact of changes in CYP 3A4 expression on oral clearance. Previous reports have identified significant alterations in CYP 3A4 expression with gestation, and given the major contribution of CYP 3A4 to overall CYP-mediated metabolic clearance, > 90 % [18, 40], this is a key component for the overall pharmacokinetics of quetiapine. The impact of gestation on the metabolic clearance of CYP 3A4 substrates has been previously reported as leading to an approximate 25-40 % increase in the clearance [22, 66]

An increase in oral clearance was observed at week 5 for pregnant subjects,  $(149.5 \text{ L/h} \pm 75.17 \text{ L})$ 

322 L/h) compared to baseline (non-pregnant) subjects at the same time point (121.9 L/h  $\pm$  51.53

L/h) (Figure 2A), however this was not statistically significant. From week 10 to 38, the oral

clearance increased, compared to baseline subjects, with week 20 demonstrating the greatest 324 difference (184.1 L/h  $\pm$  100.5 L/h) (P < 0.001) (Figure 2A). Further, an increase in total body 325 water and plasma volume that occur throughout gestation did not have a significant impact on 326 the Vss until week 25, where Vss reached 357.2 L  $\pm$  71.9 L, compared to 329.2 L  $\pm$  71 L for 327 non-pregnant subjects (Figure 2B). Previous reports have demonstrated Vss can range from 328 400-800 L for non-pregnant subjects, for both single and multidose studies [67-69]. The 329 approximate 10 % increase in Vss during gestation, although significant, may only contribute 330 a minor role to the change in trough concentration. A net increase in the unbound fraction 331 plasma (fu<sub>plasma</sub>) (21-26 % greater from weeks 30 onwards) was also simulated when comparing 332 baseline (Figure 2C). This net increase would result in an increase in circulating unbound drug, 333 resulting in an increase in the volume of distribution whilst also partly contributing to 334 potentially enhanced exposure of drug to the liver. However, the conceptualisation of this 335 effect on trough levels is multifaceted. The gestation-mediated increase in CYP 3A4 hepatic 336 abundance negates the impact of an increase in the volume of distribution and results in a net 337 reduction in trough plasma concentration (Figure 3). 338

To address the reduction in quetiapine plasma concentrations during gestation, we assessed the 339 impact of dose escalation which was required to recapitulate trough plasma concentrations to 340 within the therapeutic window. Because of the uncertainty surrounding the precise range of 341 the therapeutic window, a lower limit was set at either 50 ng/mL or 100 ng/mL (see section 342 2.4). In non-pregnant subjects, a 200 mg twice daily dose yielded a median steady-state trough 343 concentration of 59.47 ng/mL  $\pm$  26.98 ng/mL, which significantly decreased during gestation 344 to a minimum of 30.55 ng/mL at GW 20 (P < 0.001, Dunn's post-hoc comparison) (Figure 4) 345 (Supplementary Materials: Section 3 Table S2). Further, this resulted in a significant number 346 of subjects failing to attain the lower therapeutic window, < 35 % of subjects for 50 ng/mL 347 (Table 4) and < 15 % of subjects for 100 ng/mL (Table 3). This trend broadly concurs with 348 those reported by Westin et al [28], where the majority of reported plasma concentrations 349 during gestation fell below the 50 ng/mL lower limit (Figure 1), highlighting the need to 350 consider dose escalation during gestation. 351

Although a dose increase to 500 mg twice daily would be sufficient to ensure 30-50 % of subjects attained the upper therapeutic window of 100 ng/mL (Table 3), a dose increase to 700 mg twice daily was identified as satisfying the requirement to attain both the 50 ng/mL and 100 ng/mL lower windows (Figure 4), with attainment of > 95 % and > 62 % of subjects respectively. Whilst trials have suggested an upper dose of 800 mg/day [2, 70, 71], higher doses of between 800-2000 mg/day [72-76] have been reported to be tolerated in acute and maintenance therapy. Further, sparse case reports are available of significantly higher overdoses of least 20-24 g being ingested with little acute effects [77, 78].

The increase in dose may warrant closer monitoring with possible monthly clinical evaluations 360 during gestation. This would allow for assessment for any worsening of mood disorder 361 symptoms during administration of higher doses of quetiapine. This can consist of trained 362 clinician administered structured interviews (e.g. SIGH-ADS[79] or MRS[80]). Furthermore, 363 364 recommendations from the Royal College of Psychiatrists Consensus Statement [81] advocated the use of scales such as the Brief Psychiatric Rating Scale (BPRS)[82] and Health of the 365 Nation Outcome Scales (HoNOS)[83] in addition to assessing adverse effects through the 366 Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS)[84], for high dose 367 368 antipsychotic use.

Given that the metabolic clearance of quetiapine is mediated largely by CYP3A4 [18], and gestation can result in a significant increase in the expression of CYP3A4 [19-21], an increase in dose would be necessary during gestation to ensure trough plasma concentrations are in excess of the lower therapeutic window.

Although limited studies have examined the need for a dose increase during pregnancy, those that have reported this have shown that a 2-to-3 fold increase in dose is required in many cases [60, 85, 86], dose increase were required in 80 % of the patients studied during pregnancy.

### 376 5. CONCLUSIONS

The primary outcome of our work is that quetiapine doses as high as 1400 mg/day may be required during gestation, which is supported by case reports and clinical studies demonstrating few adverse clinical effects when using at doses of in excess of 800 mg/day.

For the first time, through the implementation of virtual clinical trials analysis, we have demonstrated that the reduction in quetiapine plasma concentrations are driven by both alterations in tissue physiology and the impact this has on the overall Vss, in addition to variation in CYP 3A4 abundance changes during gestation. However, for other antipsychotics, this phenomenon would largely depend upon the gestational changes in specific CYP isozymes. For example, clozapine metabolic clearance is primarily mediated by CYP 1A2, which itself can undergo significant decreases in pregnancy.

387 Further studies are required to assess both the extent of this gestational change on plasma

concentrations but also to also better identify a potential therapeutic range to better optimise

any necessary dose adjustments. However, we believe this study will provide a pragmatic basis

390 with which to consider dose adjustment throughout gestation.

391

392

### **393 CONFLICTS OF INTEREST**

394 The authors declare that they have no conflicts of interest.

### 395 ACKNOWLEDGEMENTS

- 396 This research received no specific grant from any funding agency in the public, commercial,
- 397 or not-for-profit sector.
- 398

### 399 **REFERENCES**

- Peuskens, J. and C.G. Link, *A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia*. Acta Psychiatr Scand, 1997. 96(4): p. 265-73.
- Arvanitis, L.A. and B.G. Miller, *Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry, 1997.* 42(4): p. 233-46.
- Hanley, G.E. and B. Mintzes, *Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance*. BMC pregnancy and childbirth, 2014. 14(1): p. 242.
- 409 4. Kennedy, D., et al., *Review of calls to an A ustralian teratogen information service*410 *regarding psychotropic medications over a 12-year period*. Australian and New
  411 Zealand Journal of Obstetrics and Gynaecology, 2013. 53(6): p. 544-552.
- 412 5. Ennis, Z.N. and P. Damkier, *Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.*414 Basic & clinical pharmacology & toxicology, 2015. 116(4): p. 315-320.
- 415 6. Small, J.G., et al., *Quetiapine in patients with schizophrenia. A high- and low-dose*416 *double-blind comparison with placebo. Seroquel Study Group.* Arch Gen Psychiatry,
  417 1997. 54(6): p. 549-57.

- 418 7. Chisolm, M.S. and J.L. Payne, *Management of psychotropic drugs during pregnancy*.
  419 Bmj, 2016. 532: p. h5918.
- Andersson, L., et al., *Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study*. Am J Obstet Gynecol, 2003. 189(1):
  p. 148-54.
- 423 9. Marcus, S.M., et al., *Depressive symptoms among pregnant women screened in obstetrics settings*. J Womens Health (Larchmt), 2003. 12(4): p. 373-80.
- Viguera, A.C., et al., *Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation.* Am J Psychiatry,
  2007. 164(12): p. 1817-24; quiz 1923.
- 428 11. Gilbert, P.L., et al., *Neuroleptic withdrawal in schizophrenic patients. A review of the*429 *literature.* Arch Gen Psychiatry, 1995. 52(3): p. 173-88.
- Baldessarini, R.J. and A.C. Viguera, *Neuroleptic withdrawal in schizophrenic patients*.
  Arch Gen Psychiatry, 1995. **52**(3): p. 189-92.
- 13. National Institute for Health and Care Excellence. *Antenatal and postnatal mental health: clinical management and service guidance (Clinical guideline [CG192])*. 2018
  [cited 2019 May]; Available from: <u>https://www.nice.org.uk/guidance/cg192/chapter/1-</u>
  <u>Recommendations</u>.
- 436 14. McAllister-Williams, R.H., et al., British Association for Psychopharmacology
  437 consensus guidance on the use of psychotropic medication preconception, in pregnancy
  438 and postpartum 2017. Journal of Psychopharmacology, 2017. 31(5): p. 519-552.
- Kim, J.J. and R.K. Silver, *Perinatal suicide associated with depression diagnosis and absence of active treatment in 15-year UK national inquiry*. Evid Based Ment Health, 2016. 19(4): p. 122.
- Huybrechts, K.F., et al., *Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations*. JAMA Psychiatry, 2016. **73**(9): p. 938-46.
- Cohen, L.S., et al., *Reproductive Safety of Second-Generation Antipsychotics: Current Data From the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics.* Am J Psychiatry, 2016. **173**(3): p. 263-70.
- 447 18. Grimm, S.W., K.R. Stams, and K. Bui, *In vitro prediction of potential metabolic drug*448 *interactions for Seroquel*. Schizophrenia Research, 1997. 24(1): p. 198.
- Hebert, M.F., et al., *Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.* Clin Pharmacol Ther, 2008. 84(2): p. 248-53.

- 452 20. Hodge, L.S. and T.S. Tracy, *Alterations in drug disposition during pregnancy:*453 *implications for drug therapy*. Expert Opin Drug Metab Toxicol, 2007. 3(4): p. 557-71.
- 454 21. Hirt, D., et al., *Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.* Antimicrobial agents and chemotherapy, 2006.
  456 50(6): p. 2079-2086.
- Tracy, T.S., et al., *Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.* Am J Obstet Gynecol, 2005. **192**(2): p. 633-9.
- Qasqas, S.A., et al., *Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation*. Cardiol Rev, 2004. 12(4): p. 201-21.
- 461 24. Pirani, B.B., D.M. Campbell, and I. MacGillivray, *Plasma volume in normal first pregnancy*. J Obstet Gynaecol Br Commonw, 1973. 80(10): p. 884-7.
- 463 25. Murphy, M.M., et al., *The pregnancy-related decrease in fasting plasma homocysteine*464 *is not explained by folic acid supplementation, hemodilution, or a decrease in albumin*465 *in a longitudinal study*. Am J Clin Nutr, 2002. **76**(3): p. 614-9.
- 466 26. Hayashi, M., et al., *Changes in urinary excretion of six biochemical parameters in normotensive pregnancy and preeclampsia*. Am J Kidney Dis, 2002. **39**(2): p. 392-400.
- Cheung, C.K., T. Lao, and R. Swaminathan, Urinary excretion of some proteins and *enzymes during normal pregnancy*. Clin Chem, 1989. 35(9): p. 1978-80.
- Westin, A.A., et al., *Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition*. Clinical pharmacology and therapeutics, 2018. 103(3): p. 477-484.
- 472 29. Baer, G.R., et al., *Addendum to OSE Safety Review of Seroquel*®, O.o.P. Therapeutics,
  473 Editor. 2016, Food and Drug Administration: Maryland, USA.
- Bateman, D.N., et al., *TOXBASE: poisons information on the internet*. Emerg Med J, 2002. 19(1): p. 31-4.
- Abduljalil, K., et al., *Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.* Clin Pharmacokinet, 2012. 51(6): p. 365-96.
- 479 32. Gaohua, L., et al., A pregnancy physiologically based pharmacokinetic (p-PBPK)
  480 model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J
  481 Clin Pharmacol, 2012. 74(5): p. 873-85.
- 482 33. Jogiraju, V.K., et al., *Application of physiologically based pharmacokinetic modeling*483 *to predict drug disposition in pregnant populations*. Biopharm Drug Dispos, 2017.
  484 38(7): p. 426-438.

- 485 34. Lu, G., et al., *Physiologically-based pharmacokinetic (PBPK) models for assessing the*486 *kinetics of xenobiotics during pregnancy: achievements and shortcomings*. Curr Drug
  487 Metab, 2012. 13(6): p. 695-720.
- Johnson, T.N., D. Zhou, and K.H. Bui, Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.
  Biopharm Drug Dispos, 2014. 35(6): p. 341-52.
- Bakken, G.V., et al., *Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5*. Drug Metab Dispos, 2009. 37(2): p. 254-8.
- Alqahtani, S. and A. Kaddoumi, Development of a Physiologically Based
  Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic
  Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by
  Receptor/Transporter Occupancy of Central Nervous System Drugs. Clin
  Pharmacokinet, 2016. 55(8): p. 957-69.
- 38. Rodgers, T., D. Leahy, and M. Rowland, *Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.* J Pharm Sci, 2005. 94(6): p. 1259-76.
- 39. Rodgers, T. and M. Rowland, *Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.* J
  Pharm Sci, 2006. 95(6): p. 1238-57.
- Grimm, S.W., et al., *Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics*. British Journal of Clinical Pharmacology, 2006. 61(1): p. 58-69.
- 41. Wong, Y.W., C. Yeh, and P.T. Thyrum, *The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine*. J Clin Psychopharmacol, 2001. 21(1): p. 89-93.
- 42. Potkin, S.G., et al., *Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine*. J Clin Psychopharmacol, 2002. 22(2): p. 174-82.
- 43. WHO Collaborative Centre for Drug Statistics Methodology. *ATC/DDD Index 2016*515 2016 [cited 2018 November]; Available from: <u>https://www.whocc.no/atc\_ddd\_index/</u>.
- 516 44. Mauri, M.C., et al., *Clinical Pharmacokinetics of Atypical Antipsychotics: An Update*.
  517 Clin Pharmacokinet, 2018.
- 45. Hiemke, C., et al., Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018. 51(1-02): p. 9-62.

- 46. Castberg, I., E. Skogvoll, and O. Spigset, *Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service*. J Clin Psychiatry, 2007. 68(10): p. 1540-5.
- 47. McConville, B.J., et al., *Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.* The Journal of clinical psychiatry, 2000. 61(4): p. 252-260.
- 48. Winter, H.R., et al., Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol, 2008. 18(1): p. 81-98.
- 49. Hasselstrom, J. and K. Linnet, *Quetiapine serum concentrations in psychiatric patients: the influence of comedication.* Ther Drug Monit, 2004. 26(5): p. 486-91.
- 533 50. Sparshatt, A., et al., *Relationship between daily dose, plasma concentrations, dopamine*534 *receptor occupancy, and clinical response to quetiapine: a review.* J Clin Psychiatry,
  535 2011. 72(8): p. 1108-23.
- 536 51. Kane, J.M., et al., *The expert consensus guideline series. Optimizing pharmacologic*537 *treatment of psychotic disorders. Introduction: methods, commentary, and summary.* J
  538 Clin Psychiatry, 2003. 64 Suppl 12: p. 5-19.
- 539 52. Boggs, D.L., et al., *Quetiapine at high doses for the treatment of refractory schizophrenia*. Schizophrenia research, 2008. **101**(1-3): p. 347-348.
- 53. Lindenmayer, J.P., et al., A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol, 2011. 31(2): p. 160-8.
- 545 54. Honer, W.G., et al., A randomized, double-blind, placebo-controlled study of the safety
  546 and tolerability of high-dose quetiapine in patients with persistent symptoms of
  547 schizophrenia or schizoaffective disorder. J Clin Psychiatry, 2012. 73(1): p. 13-20.
- 548 55. Pinheiro, E.A., K.L. Wisner, and C.T. Clark, *Quetiapine Dose Adjustments in Pregnant*549 *and Postpartum Women With Bipolar Disorder*. J Clin Psychopharmacol, 2018. 38(1):
  550 p. 89-91.
- 551 56. Gentile, S., *Quetiapine-fluvoxamine combination during pregnancy and while* 552 *breastfeeding*. Arch Womens Ment Health, 2006. **9**(3): p. 158-9.
- 553 57. Yaris, F., et al., *Use of polypharmacotherapy in pregnancy: a prospective outcome in a case.* Prog Neuropsychopharmacol Biol Psychiatry, 2004. **28**(3): p. 603-5.

- 555 58. Taylor, T.M., et al., *Safety of quetiapine during pregnancy*. Am J Psychiatry, 2003.
  556 160(3): p. 588-9.
- 557 59. Tenyi, T., M. Trixler, and Z. Keresztes, *Quetiapine and pregnancy*. Am J Psychiatry, 2002. **159**(4): p. 674.
- 60. Cabuk, D., et al., *Quetiapine use for the treatment of manic episode during pregnancy*.
  Arch Womens Ment Health, 2007. 10(5): p. 235-6.
- 561 61. Edginton, A.N., W. Schmitt, and S. Willmann, Development and evaluation of a
  562 generic physiologically based pharmacokinetic model for children. Clin
  563 Pharmacokinet, 2006. 45(10): p. 1013-34.
- 62. Ginsberg, G., et al., *Physiologically based pharmacokinetic (PBPK) modeling of*565 *caffeine and theophylline in neonates and adults: implications for assessing children's*566 *risks from environmental agents.* J Toxicol Environ Health A, 2004. 67(4): p. 297-329.
- 567 63. Parrott, N., et al., Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin Pharmacokinet, 2011.
  569 50(9): p. 613-23.
- 570 64. U.S. Food and Drug Administration. Summary Minutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. 2012 [cited 2018 29th May];
  572 Available from: <u>https://wayback.archive-</u>
  573 <u>it.org/7993/20170403224110/https://www.fda.gov/AdvisoryCommittees/Committees</u>
  574 <u>MeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPh</u>
  575 armacology/ucm286697.htm.
- 576 65. Olafuyi, O. and R.K.S. Badhan, *Dose Optimization of Chloroquine by Pharmacokinetic*577 *Modeling During Pregnancy for the Treatment of Zika Virus Infection*. J Pharm Sci,
  578 2019. 108(1): p. 661-673.
- 579 66. Villani, P., et al., *Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women*. Br J Clin Pharmacol, 2006. 62(3): p. 309-15.
- 581 67. Thyrum, P.T., Y.W. Wong, and C. Yeh, *Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment*. Prog Neuropsychopharmacol Biol Psychiatry, 2000. 24(4): p. 521-33.
- 584 68. DeVane CL, M.J., *Drugs as substances of metabolic enzymes: antipsychotics.*, T.K.
  585 Levy RH, Trager WF, Hansten PD, Eichelbaum M,, Editor. 2000, Lippincott-Raven
  586 Press: Baltimore (MD).

69. Gefvert, O., et al., *Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.* Psychopharmacology (Berl), 1998. 135(2):
p. 119-26.

- 70. Purdon, S.E., et al., *Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol.* J Psychiatry Neurosci, 2001. 26(2): p. 13749.
- 594 71. Copolov, D.L., C.G. Link, and B. Kowalcyk, *A multicentre, double-blind, randomized*595 *comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia.*596 Psychol Med, 2000. **30**(1): p. 95-105.
- Nagy, J., *Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up.* Int J Psychiatry Clin Pract, 2005. 9(1): p. 16-21.
- 599 73. Pierre, J.M., et al., *High-dose quetiapine in treatment refractory schizophrenia*.
  600 Schizophr Res, 2005. **73**(2-3): p. 373-5.
- 601 74. Cornelis, C., et al., A case of dose escalation of quetiapine in persistent insomnia disorder. Acta Clin Belg, 2017. 72(5): p. 346-348.
- Khazaal, Y., et al., Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. Psychiatr Q, 2013. 84(3): p. 329-35.
- Khazaal, Y., et al., *Quetiapine dosage in bipolar disorder episodes and mixed states.*Prog Neuropsychopharmacol Biol Psychiatry, 2007. 31(3): p. 727-30.
- 608 77. Balit, C.R., et al., *Quetiapine poisoning: a case series*. Ann Emerg Med, 2003. 42(6):
   609 p. 751-8.
- 610 78. Harmon, T.J., et al., *Loss of consciousness from acute quetiapine overdosage*. J Toxicol
  611 Clin Toxicol, 1998. 36(6): p. 599-602.
- 612 79. Williams, J. and M. Terman, *Structured interview guide for the Hamilton depression*613 *rating scale with atypical depression supplement (SIGH-ADS)*. New York: New York
  614 State Psychiatric Institute, 2003.
- 80. Endicott, J. and R.L. Spitzer, *A diagnostic interview: the schedule for affective disorders and schizophrenia*. Archives of general psychiatry, 1978. 35(7): p. 837-844.
- 81. Psychiatrists, R.C.o., *Consensus statement on high-dose antipsychotic medication*.
  618 CR190 ed. 2014: Royal College of Psychiatrists.
- 619 82. Overall, J.E. and D.R. Gorham, *The Brief Psychiatric Rating Scale*. Psychological
  620 Reports, 1962. 10(3): p. 799-812.
- 83. Wing, J., et al., *Health of the Nation Outcome Scales (HoNOS): research and development.* The British Journal of Psychiatry, 1998. 172(1): p. 11-18.

- Bay, J.C., et al., A self-rating scale for measuring neuroleptic side-effects. Validation *in a group of schizophrenic patients*. Br J Psychiatry, 1995. 166(5): p. 650-3.
- 85. Pinheiro, E.A., K.L. Wisner, and C.T. Clark, *Quetiapine Dose Adjustments in Pregnant and Postpartum Women With Bipolar Disorder*. Journal of clinical
  psychopharmacology, 2018. **38**(1): p. 89-91.
- 86. Uguz, F., Prophylactic use of olanzapine and quetiapine from pregnancy to the postpartum period in women with bipolar disorder: a case series. J Matern Fetal
  830 Neonatal Med, 2017. 30(21): p. 2569-2571.

### 632 Table 1: Summary pharmacokinetics parameters for validation studies in non-pregnant subjects

633

634	Study	Sampling day		C <sub>max</sub> (ng/mL)	t <sub>max</sub> (h)	AUC (ng/mL.h) <sup>a</sup>
635		Day 1	Predicted	42.53 (25.32)	1 (0.23)	144.29 (97.29)
000		Day 1	Observed	45	1.25	181
636		Day 6	Predicted	123.02 (27.76)	1.28 (0.29)	1002.99 (409.18)
637		+Ketoconazole	Observed	150	1.25	1123
007	Grimm[40]					
638		Day 0		663.42 (405.11)	1 (0.23)	2784.12 (2317)
639		Day 9	Observed	1042	1.5	4650
000		<b>Day 34</b>		320.61 (131.19)	0.93 (0.22)	1137 (650.54)
640		+Carbamazepine	Observed	205	1.3	621
641						
011		D 9	Predicted	765.48 (339.7)	1 (0.22)	3168.82 (1673.07)
642	Wan a [41]	Day 8	Observed	1048 (363)	1.4 (0.5)	3642 91375)
643	Wong[41]	Day 8	Predicted	439.01 (267.12)	0.94 (0.21)	1414.03 (1167.38)
		+Phenytoin		359 (328)	1.13 (0.36)	728 (445)
644	Potkin [42]	Day 21	Predicted	1032.71(50)	0.98 (0.65-1.40)	4223.86 (61)
645		Day 21	Observed	1124.6 (31.9)	1.23 (0.5-3)	4508.9 (39.8)
				. /	· /	· /

646

647 Data represents mean (Standard deviation). <sup>a</sup> Calculated for current dosing period.

	Baseline					
	a	<b>T1</b>	<b>T2</b>	Т3		
		(ng/mL)				
Median	59.47	28.07	24.94	26.43		
Mean	54.59	39.12	34.66	36.74		
SD	26.98	29.09	25.26	26.41		
SEM	4.61	6.20	5.38	5.63		
CI high	47.71	46.82	41.39	44.18		
CI low	31.09	22.16	19.96	21.23		
Change (%) <sup>b</sup>		52.81	58.06	55.53		

### **Table 2: Trough plasma quetiapine concentration during pregnancy**

649

T1-T3 refers to each trimester; Data calculated from mid-point of each trimester; CI:
confidence interval; SD: Standard deviation; SEM: standard error of the mean. <sup>a</sup> Baseline

652 represents non-pregnant females; <sup>b</sup> Change refers to % changes from baseline.

- 653
- 654
- 655

# Table 3: Percentage of subjects with quetiapine trough concentrations greater than 50 and 100 ng/mL

	Dose Adjustment (mg)									
50 ng/mL lower limit				100 ng/mL lower limit						
Week	Baseline	100	300	500	Baseline	100	300	500		
5	34	66	86	98	14	24	55	81		
10	28	58	82	97	9	21	43	73		
15	25	48	75	96	6	19	34	69		
20	24	45	72	95	4	18	33	65		
25	24	44	72	95	4	16	32	63		
30	24	45	74	95	4	18	33	62		
35	28	54	81	96	9	20	38	68		
38	31	60	83	96	12	22	44	69		

Data calculated from day 1 of each week; Baseline represents non-pregnant females.

### 660 LIST OF FIGURES

661

### **Figure 1: Simulated quetiapine plasma concentrations during gestation**

Simulated quetiapine plasma concentrations were generated during gestation using the Simcyp 663 Pregnancy population group, with the population group (n=33) redefined on a daily basis to 664 update study group physiology during gestation. Simulated concentrations represent post-dose 665 (trough concentrations) sampled 10 hours after dosing. Subjects were administered a 200 mg 666 twice daily dose (dose escalated from 25 mg twice daily over 1 week). 'Baseline' refers to 667 668 non-pregnant females. Simulated concentrations represent post-dose (trough concentrations) sampled 10 hours after dosing and collated at 5-week intervals over the gestation period. Red 669 open circles represent observed (pooled) plasma concentrations obtained from a total of 33 670 subjects. Black open circles present simulated plasma concentrations. 671

672

# Figure 2: Impact of physiological alterations during pregnancy on quetiapine pharmacokinetics

675 Changes in quetiapine (A) clearance, (B) volume of distribution and (C) unbound fraction in

plasma at baseline (non-pregnant females) and during gestation. Gestational week is indicated

by GW. Box-plots ideates range (upper and lower bars) with calculation of median and 25<sup>th</sup>/75<sup>th</sup>

678 percentiles. \* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001; \*\*\*\* P < 0.0001.


# Figure 3: Impact of alterations in Kp and CYP 3A4 abundance during pregnancy on quetiapine plasma concentrations


- (A) The impact of changes in Kp scalar and CYP 3A4 hepatic abundance on quetiapine
- plasma concentrations following multiple 200 mg oral doses (12-hourly). Solid lines
- represent fixed CYP 3A4 abundance but increasing Kp scalar, with dashed lines representing
- changes in Kp scalar but fixed CYP 3A4 abundance. (B) A sensitivity analysis comparing
- the impact of variation in Kp scalar (1 to 3) and CYP 3A4 abundance (137 to 180 pmol/mg
- protein) on final dose trough plasma concentrations in non-pregnant (red) and GW10 to 30.

688

### **Figure 4: Dose optimisation of quetiapine during gestation**


- 690 The impact of dose escalation on median quetiapine plasma concentrations during gestation.
- Box-plots indicate range (upper and lower bars) with calculation of median and 25<sup>th</sup>/75<sup>th</sup>
- 692 percentiles. Baseline dose was 200 mg twice daily with escalation indicated as the additive
- 693 increase in dose from baseline. Dark shaded region indicates the proposed therapeutic
- 694 window (100-500 ng/mL) with the lighter shaded region (50-100 ng/mL) indicating the
- 695 proposed 'extended' range of the therapeutic window.









162x277mm (300 x 300 DPI)





249x206mm (600 x 600 DPI)



**Gestational Week** 

# Plasma concentration (ng/mL)